time-limited venetoclax-rituximab in r/r cll patients previously exposed to btki’s
Published 10 months ago • 142 plays • Length 2:04Download video MP4
Download video MP3
Similar videos
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
1:01
pirtobrutinib, venetoclax, and rituximab in the treatment of r/r cll: insights from the bruin trial
-
1:51
the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
-
1:34
time-limited vs continuous therapy in cll treatment
-
2:25
update from murano trial: venetoclax-rituximab leads to slower clonal growth rate in cll
-
9:16
protrombin time (pt) & activated partial tromboplastin time (aptt)|coagulation analyzer|wila djami
-
4:05
comparing continuous and fixed duration therapy in cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
3:13
selection for time-limited & continuous therapy in cll
-
1:41
oral time-limited duvelisib/venetoclax in r/r cll
-
2:50
gaia/cll13: venetoclax-based time-limited combination therapies in cll
-
2:07
moving towards time-limited treatment in frontline cll
-
1:39
retreatment with a btki plus venetoclax after relapse is effective in cll: insights from captivate
-
2:20
murano: venetoclax rituximab in birc3-mutated r/r cll
-
3:17
recurrent genomic alterations in patients with cll treated with venetoclax following a bcri
-
2:59
clinical trial updates and time-limited therapy in cll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:28
a long-term analysis of lenalidomide and rituximab for the treatment of cll
-
10:20
eha22: time-limited venetoclax-obinutuzumab /- ibrutinib is superior to chemoimmunotherapy in ...
-
3:46
long-term follow-up of venetoclax in cll
-
1:17
optimizing initial therapy in cll: time-limited, all-oral approaches